Accipiter Capital Management Holding in Teva Pharm Adr (TEVA) Cut by $3.24 Million as Market Valuation Declined; Rosetta Stone (RST) Shareholder Osmium Partners Lowered Its Holding by $2.50 Million

April 20, 2018 - By Lawrence Diaz

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Gabe Hoffman decreased its stake in Teva Pharm Adr (TEVA) by 29.81% based on its latest 2017Q4 regulatory filing with the SEC. Accipiter Capital Management Llc sold 180,121 shares as the company’s stock declined 11.04% with the market. The hedge fund run by Gabe Hoffman held 424,064 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $8.04M, down from 604,185 at the end of the previous reported quarter. Accipiter Capital Management Llc who had been investing in Teva Pharm Adr for a number of months, seems to be less bullish one the $18.21B market cap company. The stock increased 1.10% or $0.195 during the last trading session, reaching $17.905. About 2.31M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 49.50% since April 20, 2017 and is downtrending. It has underperformed by 61.05% the S&P500.

John H Lewis decreased its stake in Rosetta Stone Inc (RST) by 9.48% based on its latest 2017Q4 regulatory filing with the SEC. Osmium Partners Llc sold 208,017 shares as the company’s stock rose 4.66% while stock markets declined. The hedge fund run by John H Lewis held 1.99 million shares of the prepackaged software company at the end of 2017Q4, valued at $24.76 million, down from 2.19 million at the end of the previous reported quarter. Osmium Partners Llc who had been investing in Rosetta Stone Inc for a number of months, seems to be less bullish one the $307.21M market cap company. The stock decreased 0.65% or $0.09 during the last trading session, reaching $13.67. About 12,731 shares traded. Rosetta Stone Inc. (NYSE:RST) has risen 36.60% since April 20, 2017 and is uptrending. It has outperformed by 25.05% the S&P500.

Among 3 analysts covering Rosetta Stone (NYSE:RST), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rosetta Stone had 5 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Barrington Research on Thursday, October 20. The firm has “Buy” rating by Barrington given on Wednesday, March 14. Zacks downgraded Rosetta Stone Inc. (NYSE:RST) on Tuesday, August 11 to “Hold” rating.

Investors sentiment increased to 1.61 in Q4 2017. Its up 0.35, from 1.26 in 2017Q3. It improved, as 10 investors sold RST shares while 21 reduced holdings. 20 funds opened positions while 30 raised stakes. 15.17 million shares or 1.48% less from 15.40 million shares in 2017Q3 were reported. Deutsche State Bank Ag owns 114,123 shares or 0% of their US portfolio. Arrowstreet Capital Ltd Partnership accumulated 0% or 52,774 shares. Ameritas Investment Inc has invested 0% in Rosetta Stone Inc. (NYSE:RST). North Amer Mngmt accumulated 13,544 shares or 0.03% of the stock. Bessemer Incorporated owns 21,900 shares for 0% of their portfolio. State Street Corporation, Massachusetts-based fund reported 286,685 shares. 33,741 were reported by Stone Ridge Asset Mngmt Limited Com. Meeder Asset Mgmt Inc holds 0% or 2,648 shares. Connor Clark & Lunn Invest Mngmt Limited has invested 0.01% in Rosetta Stone Inc. (NYSE:RST). Roumell Asset Mgmt Limited Liability Corp holds 10.79% of its portfolio in Rosetta Stone Inc. (NYSE:RST) for 403,848 shares. Goldman Sachs Group invested 0% in Rosetta Stone Inc. (NYSE:RST). Macquarie Grp Incorporated Ltd accumulated 29,037 shares or 0% of the stock. Mufg Americas Holdings owns 105 shares or 0% of their US portfolio. D E Shaw And Incorporated invested 0% in Rosetta Stone Inc. (NYSE:RST). Geode Mngmt Limited Liability Company has 0% invested in Rosetta Stone Inc. (NYSE:RST) for 137,038 shares.

Analysts await Rosetta Stone Inc. (NYSE:RST) to report earnings on May, 8. They expect $-0.39 EPS, down 1,075.00% or $0.43 from last year’s $0.04 per share. After $-0.14 actual EPS reported by Rosetta Stone Inc. for the previous quarter, Wall Street now forecasts 178.57% negative EPS growth.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 149 analyst reports since July 21, 2015 according to SRatingsIntel. Guggenheim upgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Friday, December 4 to “Buy” rating. As per Friday, February 10, the company rating was downgraded by Mizuho. The rating was maintained by RBC Capital Markets on Friday, June 16 with “Buy”. As per Friday, September 2, the company rating was upgraded by Oppenheimer. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Neutral” rating by BTIG Research on Friday, April 7. The stock has “Hold” rating by Piper Jaffray on Thursday, August 3. The company was maintained on Wednesday, August 30 by Cantor Fitzgerald. Credit Suisse downgraded the stock to “Sell” rating in Tuesday, September 5 report. The rating was downgraded by Jefferies to “Hold” on Wednesday, November 16. As per Tuesday, January 23, the company rating was maintained by Oppenheimer.

Rosetta Stone Inc. (NYSE:RST) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>